Anti-PD-L1 cancer immunotherapy antibodies

Inventors

Li, Chiang J. • UNNIRAMAN, SHYAM • BADER, HANNAH • JHA, MITHILESH

Assignees

1globe Biomedical Co Ltd Aka Qiangxin Institute Of Technology • 1Globe Biomedical Co Ltd • 1Globe Health Institute LLC

Abstract

Provided are compositions and methods relating to or derived from anti-PD-L1 antibodies with ADCC and/or CDC activities. More specifically, provided are fully human antibodies that bind PD-L1, PD-L1-binding antibody fragments, derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments.

Core Innovation

The invention is directed to an antigen-binding polypeptide that binds to a human PD-L1 epitope. The polypeptide comprises a heavy chain variable domain and a light chain variable domain containing respective PD-L1-specific sequences defined as sequence pairings selected from SEQ ID NO: 18 with SEQ ID NO: 20, SEQ ID NO: 42 with SEQ ID NO: 44, or SEQ ID NO: 34 with SEQ ID NO: 36.

The described subject matter further encompasses antigen-binding polypeptides configured as fully human antibodies and including a human constant region. In these embodiments, the human constant region comprises ADCC and/or CDC activities, linking PD-L1 epitope binding to effector functions. The polypeptides are also provided in antigen-binding formats and sequence embodiments such as fragments and derivatives.

In addition to the antigen-binding polypeptide, the invention provides nucleic acids encoding the polypeptide, including DNA or RNA encoding embodiments, and mammalian expression systems for producing the polypeptide. The document also provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient, carrier or diluent with the antigen-binding polypeptide, and therapeutic treatment and prophylaxis methods for human subjects using these compositions for cancers characterized by detectable PD-L1 expression in tumor cells.

Claims Coverage

The independent claims cover antigen-binding polypeptides that bind to a human PD-L1 epitope, defined by specific heavy-chain/light-chain variable domain sequence pairings, and a method of treating a human subject with cancer using a pharmaceutical composition containing such polypeptides. The inventive features are anchored by three alternative SEQ ID NO pairing sets plus the treatment administration context with those same SEQ ID-based polypeptides.

Overall, the independent-claim scope is centered on PD-L1 epitope-binding antigen-binding polypeptides whose heavy and light chain variable domains are defined by specified SEQ ID NO pairings. A further independent claim covers therapeutic treatment of a human subject with cancer by administering a pharmaceutical composition containing such PD-L1-binding polypeptides.

Stated Advantages

Documented Applications